Enalapril

Generic Name: Enalapril

Brand Names: Epaned, Vaseretic, Vasotec, Aqumeldi

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅

CAS Number: 75847-73-3

Unique Ingredient Identifier: 69PN84IO1A

Background: Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-a...

Indication: Indicated for the management of essential or renovascular hypertension as monotherapy or in combination with other antihypertensive agents, such as thiazide diuretics, for an additive effect.

Indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.
...

Associated Conditions: Diabetic Nephropathy, Hypertension, Symptomatic Congestive Heart Failure, Asymptomatic Left ventricular dysfunction

Associated Therapies: -

Clinical Trials

An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))

Phase 3

Completed

Conditions: Proteinuria

Interventions: Other: Placebo (Losartan)
Drug: Losartan Potassium
Drug: Enalapril Maleate

First Posted Date: 2007-12-05

Last Posted Date: 2024-05-23

Lead Sponsor: Organon and Co

Target Recruit Count: 306

Registration Number: NCT00568178

A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006)

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: MK8141
Drug: Enalapril

First Posted Date: 2007-10-15

Last Posted Date: 2015-10-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 160

Registration Number: NCT00543413

Chicken-Diet vs. Enalapril to Reduce Albuminuria

Not Applicable

Completed

Conditions: Microalbuminuria
Diabetic Nephropathy

First Posted Date: 2007-06-08

Last Posted Date: 2007-06-08

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 28

Registration Number: NCT00484068

Locations: 🇧🇷
HCPortoAlegre, Porto Alegre, RS, Brazil

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Enalapril
Drug: Valsartan
Drug: placebo matched to valsartan
Drug: placebo matched to enalapril

First Posted Date: 2007-03-13

Last Posted Date: 2011-07-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 250

Registration Number: NCT00446511

Locations: 🇫🇷
Sites in France, France, France
🇮🇳
Sites in India, India, India
🇵🇱
Sites in Poland, Poland, Poland

and more 6 locations

Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Valsartan
Drug: Enalapril

First Posted Date: 2007-02-12

Last Posted Date: 2011-05-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT00433836

Locations: 🇮🇹
Sites in Italy, Sites in Italy, Italy
🇫🇷
Sites in France, Sites in France, France
🇸🇪
Sites in Sweden, Sites in Sweden, Sweden

and more 8 locations

Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Macroalbuminuric Diabetic Nephropathy

First Posted Date: 2007-01-09

Last Posted Date: 2011-08-04

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 80

Registration Number: NCT00419835

Locations: 🇧🇷
Nephrology Department, Sao Paulo University Medical School, Sao Paulo, Brazil

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Phase 4

Completed

Conditions: Heart Failure
Ventricular Dysfunction, Left

Interventions: Drug: Captopril
Drug: Enalapril
Drug: Lisinopril
Drug: Ramipril
Drug: Trandolapril
Drug: Bisoprolol
Drug: Carvedilol
Drug: Metoprolol succinate
Drug: Candesartan
Drug: Valsartan
Drug: Eplerenone
Drug: Spironolactone
Drug: Diuretics
Drug: HF treatment according to Swedish guidelines
Procedure: Blood samples
Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)

First Posted Date: 2006-10-25

Last Posted Date: 2012-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 252

Registration Number: NCT00391846

Locations: 🇸🇪
Research Site, Vaxjo, Sweden

Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients

Phase 4

Completed

Conditions: Cardiotoxicity
Chemotherapeutic Toxicity

Interventions: Drug: Enalapril

First Posted Date: 2006-02-16

Last Posted Date: 2017-02-09

Lead Sponsor: European Institute of Oncology

Target Recruit Count: 114

Registration Number: NCT00292526

Locations: 🇮🇹
European Institute of Oncology, Milan, Italy

DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Hypertension

First Posted Date: 2006-01-10

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 250

Registration Number: NCT00274118

Locations: 🇳🇱
Bosch Medicentrum, Den Bosch, Netherlands
🇳🇴
Hjertelaget Research Foundation, Stavanger, Norway
🇩🇰
Medical Dept. B0642, Hillerød, Denmark

and more 17 locations

The Use of ACE Inhibitors in the Early Renal Post-transplant Period

Phase 1

Completed

Conditions: Renal Transplant

Interventions: Drug: Placebo
Drug: enalapril

First Posted Date: 2005-12-26

Last Posted Date: 2019-02-07

Lead Sponsor: Montefiore Medical Center

Target Recruit Count: 110

Registration Number: NCT00270153

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy